Skip to main content
Clinical Trials/JPRN-UMIN000008863
JPRN-UMIN000008863
Completed
未知

Evaluation of the usefulness of anti-cholinergic and B(Beta)3 agonist in patients with OAB. - Search of the clinical efficacy and safety for the Overactive bladder patients Received by imidafenacin and mirabegron as Therapeutic agents (SORT Study)

Clinical Research Support Center Kyushu0 sites400 target enrollmentOctober 1, 2012

Overview

Phase
未知
Intervention
Not specified
Conditions
Overactive bladder
Sponsor
Clinical Research Support Center Kyushu
Enrollment
400
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2012
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Clinical Research Support Center Kyushu

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Patients who has contraindication of Imidafenacin 2\)Patients who has contraindication of Mirabegron 3\)Patients with urinary flow decreased 4\)Patients with history of urinary retention 5\)Patients with arrhythmia 6\)Patients with hypokalemia 7\)Patients with serious kidney dysfunction 8\)Residual urine volume is more than 100mL 9\)Patients with bladder cancer, urinary tract stones, symptomatic urinary tract infection, recurrent urinary tract infection and interstitial cystitis. 10\)Patients with polyuria 11\)Patients who have administered prohibited substances or done prohibited therapy within the 4 weeks before enrollment 12\)Patients who have a urology or genital surgery within the 6 months before enrollment 13\)Patients with history of resistance to anti\-holinergic agents 14\)Lower urinary tract symptoms aren't stable. 15\)Any other patients who are regarded as unsuitable for this study by the investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials